Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back

By Brian Feroldi - Jul 13, 2017 at 12:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares popped after the company released the pricing details of its recently announced stock offering.

What happened

Investors in Alder Biopharmaceuticals (ALDR) are having another wild day. Shares of the clinical-stage biopharma rose as much as 15.5% on Thursday after the company released the pricing details of its just announced common-stock offering. As of 12:43 p.m. EDT, the stock was up 13.7%.

So what

Alder stated that it is selling 15 million shares of its common stock for $10 each. In addition, the underwriters of the deal have been granted a 30-day option to purchase up to 2.25 million additional shares at the offering price. The deal is expected to close early next week and could add up to $172.5 million to the company's bank account before subtracting fees.

Rising stock chart superimposed on digital map of the world

Image source: Getty Images.

Investors are likely reacting favorably to this news for two reasons: First, the $10 deal price only represents a tiny discount to yesterday's closing price of $10.13.  Second, the original announcement called for the company to sell 12.5 million shares to the public and up to 1.875 million additional shares to the underwriters. The fact that the company was able to sell 15 million shares to the public and up to 2.25 million to the underwriters suggests that there was plenty of demand for the company's stock.

On the flip side, selling more shares to the public means that existing shareholders will face even more dilution. The updated terms of this deal could dilute current shareholders by more than 34% if underwriters fully exercise their option. 

Now what

Given that Alder lost more than $100 million last quarter, I think it's good news that the company was able to raise more money than initially expected. However, since Alder's stock was trading over $36 earlier this year, I have a hard time getting excited about the $10 offering price.

Regardless of the dilution, the bull case for owning Alder's stock from here still rests upon the success of its lead compound, eptinezumab, as a hopeful treatment for migraines. Given the so-so results from its phase 3 trial, I still have doubts about this drug's ability to compete against Eli Lilly's galcanezumab. For that reason, my personal plan is to keep Alder's stock far away from my portfolio.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alder BioPharmaceuticals, Inc. Stock Quote
Alder BioPharmaceuticals, Inc.
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$302.50 (0.39%) $1.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.